DRC receives over 16,000 doses of Ervebo vaccine amid Ebola outbreak

More than 16,000 doses of Ervebo vaccine have been delivered to the Democratic Republic of Congo as health officials intensify efforts to control an ongoing Ebola outbreak in the country.

The vaccine, manufactured by Merck, is approved and proven effective against the Zaire strain of Ebola virus disease. However, the current outbreak is being driven by the Bundibugyo strain, raising concerns about the vaccine's protective capacity against this variant.

Health authorities in the DRC have been working to contain the spread of Ebola, which causes severe illness and has a high fatality rate. The arrival of the vaccine doses represents a significant step in the response effort, though deployment strategies will likely focus on managing confirmed cases and their contacts.

The shipment underscores the importance of having multiple intervention tools available during outbreaks, even as questions persist about cross-strain protection. International health organisations continue to monitor the situation closely as the DRC implements containment and vaccination programmes.

Ebola outbreaks in Central Africa have claimed thousands of lives over the past decade, making vaccine availability a critical component of disease control strategies across the region.